Persistent olmesartan-based blood pressure–lowering effects on morning hypertension in Asians: the HONEST study

[1]  Satoshi Teramukai,et al.  Home Blood Pressure and Cardiovascular Outcomes in Patients During Antihypertensive Therapy: Primary Results of HONEST, a Large-Scale Prospective, Real-World Observational Study , 2014, Hypertension.

[2]  T. Ogihara,et al.  Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1 , 2014, Journal of hypertension.

[3]  G. Parati,et al.  Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone , 2014, Hypertension Research.

[4]  K. Kario,et al.  Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST Study at 16 weeks , 2013, Journal of Human Hypertension.

[5]  K. Kario,et al.  Enhanced Blood Pressure–Lowering Effect of Olmesartan in Hypertensive Patients With Chronic Kidney Disease–Associated Sympathetic Hyperactivity: HONEST Study , 2013, Journal of clinical hypertension.

[6]  S. Umemura,et al.  Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study , 2013, Hypertension Research.

[7]  K. Kario,et al.  Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension , 2013, Drugs in R&D.

[8]  K. Kario,et al.  The Effects of the L / N‐Type Calcium Channel Blocker (Cilnidipine) on Sympathetic Hyperactive Morning Hypertension: Results From ACHIEVE‐ONE * , 2013, Journal of clinical hypertension.

[9]  K. Kario,et al.  Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study , 2012, Hypertension Research.

[10]  Kazuomi Kario,et al.  Nighttime Home Blood Pressure and the Risk of Hypertensive Target Organ Damage , 2012, Hypertension.

[11]  J. Staessen,et al.  Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure , 2012, Hypertension Research.

[12]  K. Asayama,et al.  Ambulatory Versus Home Versus Clinic Blood Pressure: The Association With Subclinical Cerebrovascular Diseases: The Ohasama Study , 2012, Hypertension.

[13]  K. Kario,et al.  Nearly Half of Uncontrolled Hypertensive Patients could be Controlled by High-dose Titration of Amlodipine in the Clinical Setting: The ACHIEVE Study , 2011 .

[14]  K. Kario,et al.  Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association , 2011, Hypertension Research.

[15]  K. Kario.  Morning Surge in Blood Pressure and Cardiovascular Risk: Evidence and Perspectives , 2010, Hypertension.

[16]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) , 2009, Hypertension Research.

[17]  Teemu J Niiranen,et al.  Home-Measured Blood Pressure Is a Stronger Predictor of Cardiovascular Risk Than Office Blood Pressure: The Finn-Home Study , 2009, Hypertension.

[18]  K. Kario,et al.  Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients , 2009, Hypertension.

[19]  K. Kario,et al.  Early morning hypertension: what does it contribute to overall cardiovascular risk assessment? , 2008, Journal of the American Society of Hypertension : JASH.

[20]  J. Redón,et al.  Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring , 2007, Journal of hypertension.

[21]  K. Kario,et al.  Effects of New Calcium Channel Blocker, Azelnidipine, and Amlodipine on Baroreflex Sensitivity and Ambulatory Blood Pressure , 2007, Journal of cardiovascular pharmacology.

[22]  Kazuomi Kario,et al.  Morning Hypertension: The Strongest Independent Risk Factor for Stroke in Elderly Hypertensive Patients , 2006, Hypertension Research.

[23]  I. Komuro,et al.  Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor* , 2006, Journal of Biological Chemistry.

[24]  S. Umemura,et al.  Current Status of Antihypertensive Prescription and Associated Blood Pressure Control in Japan , 2006, Hypertension Research.

[25]  M. Pugsley,et al.  A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker , 2005, Journal of cardiovascular pharmacology.

[26]  Roberto Sega,et al.  Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study , 2005, Circulation.

[27]  K. Kario,et al.  Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. , 2004, American journal of hypertension.

[28]  P. Elliott,et al.  Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: The INTERMAP Study , 2003, Journal of Human Hypertension.

[29]  Kazuhiko Ishikawa,et al.  Salt sensitivity of Japanese from the viewpoint of gene polymorphism. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[30]  Kazuomi Kario,et al.  Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives: A Prospective Study , 2003, Circulation.

[31]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[32]  R. MacInnis,et al.  ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. , 2001, American journal of hypertension.

[33]  Shigeru Hisamichi,et al.  Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan , 1998, Journal of hypertension.

[34]  H. Koike,et al.  Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. , 1995, European journal of pharmacology.

[35]  A. Chobanian,et al.  Guidelines for the Management of Hypertension. , 2017, The Medical clinics of North America.

[36]  Yutaka Imai,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) , 2014, Hypertension Research.

[37]  T. Murohara,et al.  Efficacy and safety of the losartan-hydrochlorothiazide combination tablet in patients with hypertension uncontrolled by angiotensin II receptor antagonist therapy: the Aichi Research on Combination therapy for Hypertension (ARCH) Study. , 2012, Internal medicine.

[38]  T. Ogihara,et al.  The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension , 2009, Hypertension Research.

[39]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .